ATOSSA THERAPEUTICS INC (ATOS) Fundamental Analysis & Valuation

NASDAQ:ATOS • US04962H7044

Current stock price

4.82 USD
-0.06 (-1.23%)
At close:
4.99 USD
+0.17 (+3.53%)
After Hours:

This ATOS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ATOS Profitability Analysis

1.1 Basic Checks

  • ATOS had negative earnings in the past year.
  • In the past year ATOS has reported a negative cash flow from operations.
  • In the past 5 years ATOS always reported negative net income.
  • ATOS had a negative operating cash flow in each of the past 5 years.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • ATOS's Return On Assets of -73.03% is on the low side compared to the rest of the industry. ATOS is outperformed by 65.18% of its industry peers.
  • The Return On Equity of ATOS (-88.35%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -73.03%
ROE -88.35%
ROIC N/A
ROA(3y)-45.89%
ROA(5y)-34.82%
ROE(3y)-52.37%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • ATOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ATOS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ATOS remains at a similar level compared to 1 year ago.
  • ATOS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • ATOS has an Altman-Z score of -5.87. This is a bad value and indicates that ATOS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ATOS (-5.87) is worse than 65.96% of its industry peers.
  • ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.87
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 5.53 indicates that ATOS has no problem at all paying its short term obligations.
  • ATOS has a Current ratio (5.53) which is in line with its industry peers.
  • ATOS has a Quick Ratio of 5.53. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
  • ATOS's Quick ratio of 5.53 is in line compared to the rest of the industry. ATOS outperforms 59.38% of its industry peers.
Industry RankSector Rank
Current Ratio 5.53
Quick Ratio 5.53
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ATOS Growth Analysis

3.1 Past

  • ATOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.25%.
EPS 1Y (TTM)-88.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-310.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ATOS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.75% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.34%
EPS Next 2Y16.92%
EPS Next 3Y24.79%
EPS Next 5Y14.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. ATOS Valuation Analysis

4.1 Price/Earnings Ratio

  • ATOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • ATOS's earnings are expected to grow with 24.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.92%
EPS Next 3Y24.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATOS Dividend Analysis

5.1 Amount

  • ATOS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATOS Fundamentals: All Metrics, Ratios and Statistics

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (4/8/2026, 8:17:01 PM)

After market: 4.99 +0.17 (+3.53%)

4.82

-0.06 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-11
Inst Owners21.47%
Inst Owner Change13.47%
Ins Owners0.04%
Ins Owner Change292.62%
Market Cap41.50M
Revenue(TTM)N/A
Net Income(TTM)-34.77M
Analysts82
Price Target65.03 (1249.17%)
Short Float %3.73%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.2%
Min EPS beat(2)-165.46%
Max EPS beat(2)-2.94%
EPS beat(4)1
Avg EPS beat(4)-43.56%
Min EPS beat(4)-165.46%
Max EPS beat(4)13.5%
EPS beat(8)4
Avg EPS beat(8)-14.43%
EPS beat(12)6
Avg EPS beat(12)-12.8%
EPS beat(16)10
Avg EPS beat(16)-6.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.27%
PT rev (3m)1008.7%
EPS NQ rev (1m)12.38%
EPS NQ rev (3m)-1214.29%
EPS NY rev (1m)11.77%
EPS NY rev (3m)-1231.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-5.93
EYN/A
EPS(NY)-3.89
Fwd EYN/A
FCF(TTM)-3.46
FCFYN/A
OCF(TTM)-3.46
OCFYN/A
SpS0
BVpS4.57
TBVpS4.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.03%
ROE -88.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.89%
ROA(5y)-34.82%
ROE(3y)-52.37%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 143.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.53
Quick Ratio 5.53
Altman-Z -5.87
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)105.46%
Cap/Depr(5y)133.28%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-310.67%
EPS Next Y34.34%
EPS Next 2Y16.92%
EPS Next 3Y24.79%
EPS Next 5Y14.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.52%
OCF growth 3YN/A
OCF growth 5YN/A

ATOSSA THERAPEUTICS INC / ATOS Fundamental Analysis FAQ

What is the fundamental rating for ATOS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATOS.


Can you provide the valuation status for ATOSSA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ATOSSA THERAPEUTICS INC (ATOS). This can be considered as Overvalued.


How profitable is ATOSSA THERAPEUTICS INC (ATOS) stock?

ATOSSA THERAPEUTICS INC (ATOS) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ATOS stock?

The Earnings per Share (EPS) of ATOSSA THERAPEUTICS INC (ATOS) is expected to grow by 34.34% in the next year.